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a–c Egypt; d Saudi ArabiaBackground: Recent data suggest that the presence of non-alcoholic fatty liver disease (NAFLD) may be linked to
increased cardiovascular and chronic kidney diseases. Here we assess whether NAFLD, as diagnosed by ultrasound,
predicts the risk of incident cardiovascular and renal impairment events.
Methods: A total of 1150 patients with normal or near normal liver and kidney functions, and without protienuria
or histories of cardiovascular accident were included in this multicenter prospective observational cohort study. All
patients were subjected to full clinical evaluation, laboratory investigation including estimation of the GFR and
immunonephelometric evaluation for protienuria, and abdominal ultrasonography for diagnosis of NAFLD. The
metabolic syndrome was defined according to the modified National Cholesterol Education Program (NCEP)–ATP
criteria. All patients followed up periodically over three years for the incidence of cardiovascular (including coro-
nary heart disease, ischemic stroke and cerebral hemorrhage) and renal impairment events.
Results: Only 747 (62.25%) patients completed the follow-up examination and were included in the final analysis.
35.8% of them fulfilled the sonographic criteria of NAFLD. The frequency of cardiovascular accident and renal
impairment was significantly higher in them: 136 patients (50.7%) vs. 110 (23%); P < 0.001 for cardiovascular events,
88 (32.8%) vs. 88 (18.4%), P < 0.001 for microalbuminuria; and 24 (8.9%) vs. 14 (2.9%), P < 0.001 for macroalbuminuria.
Also, mean estimated glomerular filtration rate (eGFR) was significantly lower in patients with NAFLD (96 ± 23.28
vs. 111 ± 28.37; P < 0.001). Logistic regression analysis revealed that NAFLD was the best predictor for cardiovascular
and renal impairment.
Conclusion: NAFLD is a good predictor of cardiovascular and renal diseases.
 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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bbreviations and Acronyms
NAFLD = non-alcoholic fatty liver disease
NCEP = national cholesterol education program
eGFR = estimated glomerular filtration rate
CKD = chronic kidney disease
CVD = cardiovascular disease
BMI = body mass index
ALT = alanine aminotransferase
AST = aspartate aminotransferase
T. = cholesterol, total cholesterol
LDL-C = low density lipoprotein cholesterol
HDL-C = high density lipoprotein cholesterol
UA = unstable angina
MI = myocardial infarction
CHD = coronary heart disease
DDM = duration of diabetes mellitus
N = number
SD = standard variation
BMI = body mass index
WC = waist circumference
FBS = fasting blood sugar
SBP = systolic blood pressure
DBP = diastolic blood pressure
DM = diabetes mellitus
HbA1c = glycosylated hemoglobin
MetS = metabolic syndrome
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Nonalcoholic fatty liver disease (NAFLD) is aclinical condition characterized by histo-
logical features resembling that of alcohol-in-
duced liver injury, but occurs in patients who
do not abuse alcohol. NAFLD encompasses a
histological spectrum ranging from simple stea-
tosis to steatohepatitis, advanced fibrosis and
cirrhosis [1].
It frequently occurs with features of the
metabolic syndrome (MetS) [2]. The MetS is
known to be a strong predictor of NAFLD and is
a well-known precursor of cardiovascular disease
(CVD), but the potential cardiovascular risk of
NAFLD itself has not been well investigated [3].
Recent cross-sectional studies have documented
that patients with NAFLD have a markedly greater
carotid artery wall thickness than those without
NAFLD [4,5]. However, carotid artery wall thick-
ness is only a marker of early generalized athero-
sclerosis [6], so it is currently uncertain whether
NAFLD is significantly associated with increased
risk of future cerebrovascular events.
Growing evidence suggests that NAFLD may
be linked to an increased risk for chronic kidney
disease (CKD) especially in a population with
type-2 diabetes [7]. The treatment of earlier
stages of nephropathy, especially in diabetes, is
effective in slowing progression toward end
stage renal disease [8,9]. Thus, the early detec-
tion of precursors and risk factors for CKD is
very important.
Objectives: To identify the prevalence of
NAFLD and to assess whether NAFLD is associ-
ated with an increased incidence of CKD and
CVD, including coronary heart disease (CHD),
ischemic stroke and cerebral hemorrhage.Patients and methods
Ethics
The study protocol was approved by the local
ethical committee. No interference with normal
routine patient management or invasive medical
procedures was required by the protocol. Investi-
gators decided on the treatment that was in the
best interest of their patients.Design
This multicenter prospective observational co-
hort study enrolled 1150 patients between January
2009 and February 2010 with normal or near nor-Amal liver and kidney functions, and without overt
protienuria or history of cardiovascular events.
Exclusion criteria
Patients with (a) previous history of CVD, includ-
ing unstable angina (UA), myocardial infarction
(MI), coronary revascularization, ischemic stroke,
cerebral hemorrhage; (b) previous history of overt
protienuria, or eGFR < 60 ml/min/1.73 m2, or were
receivingmedical treatment for current kidney dis-
easeat the timeof their initial examinations; (c)with
known history of liver disease including viral, ge-
netic, autoimmune, anddrug-induced liver disease
or those with positive test for hepatitis B antigen or
hepatitis C antibody; and (d) with a history of alco-
hol intake or cancer.
Prior to starting the study, the objectives and
methods were explained to all patients.
Evaluation of patients
All patients were subjected to:
(1) Full clinical evaluation: Special emphasis on
history of smoking and alcohol consumption,
assessment of vital signs (including BP; mea-
sured in the supine position after 15 min of
bed rest), and symptoms of renal impairment
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ation. Body mass index (BMI) was calculated
as body weight in kilograms divided by the
square of the participant’s height in meters.
Waist circumference (WC) was measured in
a standing position at the level of the
umbilicus.
(2) Laboratory investigations
 Routine labs, including liver function test: ala-
nine aminotransferase (ALT) and aspartate
aminotransferase (AST); hepatitis B antigen
and hepatitis C antibody; kidney function tests:
creatinine and urea; FBS; HbA1c; urine analysis;
lipid profile (Total cholesterol, LDL-C, HDL-C
and serum triglyceride using 12–14 h fasting
blood sample).
 Lab specific for the study:
(i) eGFR:- according to the Modification of Diet in Renal
Disease (MDRD) equation: [10]eGFRðml=min=1:73 m2Þ ¼ 186 ðCreatinine=88:4Þ1:154
 ðAgeÞ0:203  ð0:742 if femaleÞ
 ð1:210if blackÞ
(i) Urinary albumin excretion ratewasmeasured
from an early morning urine sample as albu-
min-to-creatinineratiobyanimmunonephelo-
metric method; microalbuminuria and
macroalbuminuria (overt proteinuria) were
present when urinary albumin excretion was
30–299 lg/mgcreatinineandP300 lg/mgcre-
atinine,respectively[8].Renalimpairmentwas
defined as eGFR 6 60 ml/min/1.73 m2 and/or
overtprotienuria.
(3) Electrocardiography.
(4) Radiological examination including abdomi-
nal ultrasound to exclude chronic liver dis-
ease and to diagnose fatty liver. This was
carried out by a trained operator blinded to
participants’ clinical and laboratory charac-
teristics. Four known criteria (hepatorenal
echo contrast, liver brightness, deep attenua-
tion, and vascular blurring) are required to
diagnose NAFLD [11].
(5) MetS components were determined accord-
ing to NCEP-ATP-III criteria [12], using the
following values: (i) WCP 102 cm for males
and P88 cm for females; (ii) Triglycerides
P150 mg/dL; (iii) HDL-C < 40 mg/dL for
males and <50 mg/dL for females; (iv) BPP
130/85 mmHg; and (v) FBSlevelP 100 mg/dL.
Patients using antihypertensive drugs or
hypoglycemic drugs are accepted as having a
positive MetS criterion. MetS is confirmed
when three of five components are present.Follow-up
The patients were followed up periodically
every 6–12 months for a period of three years, for
the incidence of cardiovascular and kidney events.
Cardiovascular events include CHD, ischemic
stroke and cerebral hemorrhage. CHD includes
UA, acute MI, silent MI and coronary revasculari-
zation. CVD was confirmed by reviewing medical
records of the hospital and electrocardiogram
changes. Non-fatal cerebrovascular accident, con-
firmed by medical records, showed new-onset
neurological symptoms lasting >24 h with diag-
nostic imaging tests (computed tomography or
nuclear magnetic resonance). Kidney events were
assessed if eGFR progressed to <60 ml/min/
1.73 m2 and/or protienuria.
Statistical analysis
Data of each patient was collected in a special
file, coded and fed to the computer on a statistical
package using SPSS software for windows, ver-
sion 18 for (SPSS Inc., Chicago IL, USA). Descrip-
tive statistics were done including mean, standard
of deviation for the non-categorical variables and
prevalence for categorical variables. Continuous
variables were evaluated using t-test and categor-
ical variables using Chi square. Logistic regression
was used to analyze correlation between the inci-
dence of cardiovascular and renal impairment
events and NAFLD. P < 0.05 will be considered
statistically significant.Results
Demographic data
All 1150 patients in this study had normal and
near normal kidney function and no overt protien-
uria or history of cardiovascular accident at base-
line. However, only 747 (64.95%) of these
patients attended and completed the follow-up
examination, and were included in the final anal-
ysis. In terms of demographic variables, eGFR,
and NAFLD status, the patients who completed
the follow-up examination were essentially similar
to the 403 (35.05%) patients who did not attend the
follow-up examinations. (Table 1).
The 268 (35.8%) patients who fulfilled the sono-
graphic criteria of NAFLD were predominantly
smokers and had significantly higher BMI. This
group also had higher systolic and diastolic BP.
Patients on antihypertensive drugs were signifi-
cantly higher (Table 2).
Diabetes mellitus (DM) was not significantly
higher in NAFLD patients with higher HbA1c but
Table 2. Clinical profile of the patients included in the final analysis in relation to NAFLD.
Variables NAFLD P value
No: N = 479 (66.2%) Yes: N = 268 (35.8%)
Age (years) Mean ± SD(range) 51.11 ± 10.65(29–78) 52.10 ± 12.46(30–78) 0.078
Sex (male) N(%) 233(48.6%) 133(49.6%) 0.245
BMI (kg/m2) Mean ± SD(range) 34.35 ± 3.8(26–45) 33.37 ± 5.11(26–45) 0.013
WC (cm) Mean ± SD(range) 105.12 ± 7.97(89–129) 105.40 ± 9.38(89–128) 0.853
Smokers N(%) 106(22.1%) 62(23.1%) <0.001
SBP (mmHg) Mean ± SD(range) 136.61 ± 14.62(110–175) 131.61 ± 14.83(110–169) <0.001
DBP (mmHg) Mean ± SD(range) 84.50 ± 8.35(70–110) 82.74 ± 8.11(70–100) 0.017
Antihypertensive N(%) 159(33.2%) 83(30.9%) <0.001
DM N(%) 218(45.5%) 213(79.4%) 0.055
FBS (mg/dL) Mean ± SD(range) 108 ± 16.16(78–158) 108.27 ± 17.98(79–146) 0.969
HbA1c (%) Mean ± SD(range) 2.78 ± 3.14(0–9) 4.96 ± 2.68(0–11.6) <0.001
DDM (years) Mean ± SD(range) 23.55 ± 29.44(0–120) 46.65 ± 30.06(0–132) <0.001
Oral hypoglycemia N(%) 204(42.5%) 180(67.2%) 0.001
Insulin therapy N(%) 24(5%) 41(15.3%) <0.001
T. cholesterol (mg/dL) Mean ± SD(range) 198.06 ± 35.65(131–294) 243.75 ± 47.48(139–345) <0.001
HDL-C (mg/dL) Mean ± SD(range) 48.02 ± 6.96(32–66) 42.94 ± 6.09(33–58) <0.001
LDL-C (mg/dL) Mean ± SD(range) 121.04 ± 23.67(80–181) 154.96 ± 30.25(80–212) <0.001
Triglyceride (mg/dL) Mean ± SD(range) 151.49 ± 44.24(69–243) 175.68 ± 51.48(78–278) <0.001
ALT (U/L) Mean ± SD(range) 49.82 ± 24.06(18–134) 70.40 ± 29.6(21–134) <0.001
AST (U/L) Mean ± SD(range) 39.66 ± 17.37(18–94) 52.68 ± 19.14(20–102) <0.001
MetS Mean ± SD(range) 2.86 ± 1.07(0–5) 3.16 ± 0.98(1–5) 0.01
MetS N(%) 294(61.4%) 212(79.1%) <0.001
Table 1. Baseline clinical profile of all included participants.
Variables Participants who
completed the follow-up period
Participants who did not
complete follow-up period
P value
N = 747 (64.95%) N = 403 (35.05%)
Age (years) Mean ± SD 51.44 ± 11.32 50.84 ± 10.46 0.201
Sex (male) N(%) 266(48.9%) 202(50.1%) 0.845
BMI (kg/m2) Mean ± SD 34 ± 4.34 34.35 ± 3.82 0.178
WC (cm) Mean ± SD 105.22 ± 8.5 105.18 ± 8.02 0.464
Smokers N(%) 166(22.48%) 86(21.3%) 0.643
SBP (mmHg) Mean ± SD 134.82 ± 14.80 136.55 ± 14.33 0.055
DBP (mmHg) Mean ± SD 83.86 ± 8.30 84.48 ± 8.20 0.231
Antihypertensive N(%) 242(32.4%) 139(34.5%) 0.605
DM N(%) 431(57.7%) 252(62.5%) 0.345
FBS (mg/dL) Mean ± SD 108.10 ± 16.82 107.90 ± 15.90 0.840
HbA1c (%) Mean ± SD 3.57 ± 3.16 3.26 ± 3.13 0.125
DDM (years) Mean ± SD 31.84 ± 29.60 31.16 ± 28.37 0.741
Oral hypoglycemia N(%) 384(51.4%) 216(53.6%) 0.675
Insulin therapy N(%) 65(8.7%) 38(9.4%) 0.706
T. cholesterol (mg/dL) Mean ± SD 214.45 ± 45.85 210.48 ± 40.88 0.145
HDL-C (mg/dL) Mean ± SD 46.19 ± 7.09 46.91 ± 7.98 0.111
LDL-C (mg/dL) Mean ± SD 133.21 ± 30.84 130.45 ± 27.68 0.133
Triglyceride (mg/dL) Mean ± SD 160.17 ± 48.35 158.73 ± 44.29 0.620
ALT (U/L) Mean ± SD 57.20 ± 27.96 57.67 ± 29.0 0.790
AST (U/L) Mean ± SD 44.34 ± 19.06 43.86 ± 20.84 0.704
MetS Mean ± SD 2.97 ± 1.05 2.89 ± 1.07 0.216
MetS N(%) 506(67.7%) 287(71.2%) 0.559
eGFR (ml/min/1.73 m2) Mean ± SD 107 ± 26.56 107 ± 24.84 0.825
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Patients using oral hypoglycemic drugs and insu-
lin therapy were also significantly higher in the
NAFLD group (Table 2).NAFLD patients also had significantly higher
levels of cholesterol, LDL-C, triglyceride and
liver enzymes and lower levels of HDL-C
(Table 2).
Table 3. The frequency of cardiovascular incident and renal impairment in relation to NAFLD.
Variables NAFLD P value
No: N = 479 (66.2%) Yes: N = 268 (35.8%)
Cardiovascular accident N(%) 110(23%) 136(50.7%) <0.001
CHD
UA N(%) 16(3.3%) 39(14.6%) <0.001
MI N(%) 21(4.4%) 16(6%) <0.001
Silent MI N(%) 21(4.4%) 25(9.3%) <0.001
Revascularization N(%) 40(8.3%) 51(19%) <0.001
Cerebrovascular
Ischemic stroke N(%) 38(7.9%) 44(16.4%) <0.001
Cerebral hemorrhage N(%) 25(5.2%) 24(9%) <0.001
Protienuria
Microalbuminuria N(%) 88(18.4%) 88(32.8%) <0.001
Macroalbuminuria N(%) 14(2.9%) 24(8.9%) <0.001
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INCIDENCE OF CARDIOVASCULAR AND RENAL EVENTSThe frequency of MetS and the mean number of
MetS risk factors were significantly higher in
those with NAFLD (Table 2).
During the follow-up period, 246 (35.8%) pa-
tients developed cardiovascular events; 131
(53.2%) patients developed cerebrovascular
events; 82 (62.6%) developed ischemic stroke; 49
(37.4%) developed cerebral hemorrhage; 138
(56.1%) developed cardiovascular events; 55
(39.9%) developed UA; 37 (26.8%) developed MI;
and 46 (33.3%) developed silent MI. Ninety one
(37%) patients underwent revascularization (60
patients for percutaneous revascularization and
31 patients for surgical revascularization).
Cardiovascular events were significantly higher
in those with sonographic findings of NAFLD
(50.7% vs. 23%, P < 0.001) (Table 3).
The baseline characteristics of patients who
developed cardiovascular events during the fol-
low-up period were: older age (59.97 ± 10.92 vs.
47.25 ± 8.92 years. P < 0.001), more likely to be male
(59.3% vs. 43.9%, P = 0.006) and more likely to be
smokers (24.7% vs. 17.9%, P = 0.03). The incidence
of DMwas significantly higher in those who devel-
oped cerebrovascular events during the follow-up
period (71.1% vs. 51.1%, P < 0.001) with signifi-
cantly higher HbA1c (4.44 ± 2.98 vs. 3.14 ± 3.16%,
P < 0.001) and with considerably longer DDM
(40.53 ± 31.91 vs. 27.56 ± 30.66 years, P < 0.001).
Also, the use of oral hypoglycemic drugs was
notably higher in these patients (63.4% vs.
45.5%, P < 0.001). However, the level of FBS and
the number of patients using insulin therapy
did not significantly differ between the two
groups (108.48 ± 16.70 vs. 107.32 ± 17.08 mg/dl,
P = 0.91 and 7.4% vs. 11.4%, P = 0.061,
respectively).They also had a significantly higher level of cho-
lesterol, LDL-C, triglyceride and liver enzymes
(P < 0.001 for all), but the level of HDL-C did not
significantly differ between the two groups
(P = 0.059).
The frequency of NAFLD was considerably
greater in those who developed cardiovascular
events during follow-up (55.3% vs. 26.3%,
P < 0.001). The frequency and the mean number
of MetS risk factors did not significantly differ be-
tween the two groups (68.7% vs. 65.9%, P = 0.44
and 3 ± 1.08 vs. 2.91 ± 0.98, P = 0.88, respectively).
During the follow-up period, 214 (28.6%) patients
developed renal impairment, 176 (82.6%) devel-
oped microalbuminuria, and 37 (17.4%) developed
macroalbuminuria. The mean eGFR was signifi-
cantly lower in those who developed renal impair-
ment (i.e. protienuria) during the follow-up period.
The frequency of renal impairment was higher
in those with sonographic findings of NAFLD.
Also, mean eGFR was significantly lower in
NAFLD group (96 ± 23.28 vs. 111 ± 28.37,
P < 0.001) (Table 3).
The baseline characteristics of patients who
developed renal impairment during the follow-up
period were: older age (52.95 ± 11.97 vs.
50.82 ± 11.04 years. P = 0.01), more likely to be
smokers (28.5% vs. 20%, P < 0.001) and had consid-
erably increased WC (106.78 ± 10.08 vs.
104.60 ± 7.7 cm, P = 0.022). The frequency of DM
was much higher in those who developed renal
impairment during follow-up (98.1% vs. 41.7%,
P < 0.001)with significantlyhigher fastingblood su-
gar (110.77 ± 18.25 vs. 107.02 ± 16.11 mg/dl,
P = 0.035) and HbA1c (6.29 ± 1.14 vs. 2.47 ± 3.05%,
P < 0.001) and much longer DDM (67.12 ± 21.26 vs.
17.67 ± 22.84 yrs, P < 0.001). The use of oral hypo-
Table 4. Logistic regression in relation to cardiovascular and renal impairment events.
Variables Cardiovascular events Renal impairment events
Exp (beta) 95%CI P value Exp (beta) 95%CI P value
Age (years) 1.027 0.65–1.61 0.907 1.006 0.97–1.03 0.670
Gender 1.159 1.13–1.18 0.005 1.147 0.63–1.85 0.646
Weight (kg) 0.983 0.94–1.02 0.377 1.015 0.97–1.05 0.451
BMI (kg/m2) 0.958 0.85–1.07 0.446 0.972 0.86–1.09 0.633
WC (cm) 1.031 0.99–1.07 0.119 1.009 0.96–1.05 0.707
Smoker (yes vs. no) 0.707 0.37–1.33 0.283 1.319 0.57–3.04 0.112
SBP (mmHg) 1016 0.98–1.04 0.293 1.033 0.99–1.07 0.071
DBP (mmHg) 0.981 0.92–1.03 0.514 0.941 0.87–1.01 0.122
Antihypertensive (yes vs. no) 1.283 0.63–2.61 0.492 1.067 0.41–2.76 0.894
FBS (mg/dL) 0.995 0.98–1.01 0.551 1.013 0.99–1.03 0.163
HbA1c (%) 1.033 0.99–1.07 0.071 0.954 0.74–1.27 0.013
DDM (years) 0.995 0.97–1.01 0.110 1.094 1.07–1.11 0.009
Oral hypoglycemia (yes vs. no) 2.709 0.65–3.27 0.171 0.305 0.04–2.09 0.228
Insulin therapy (yes vs. no) 1.984 0.50–3.82 0.327 0.321 0.05–1.96 0.219
T. cholesterol (mg/dL) 1.014 0.99–1.03 0.061 1.015 1.00–1.02 0.011
HDL-C (mg/dL) 0.982 0.95–1.01 0.237 0.970 0.92–1.02 0.250
LDL-C (mg/dL) 1.003 0.99–1.01 0.024 0.998 0.98–1.01 0.756
Triglyceride (mg/dL) 1.001 0.99–1.01 0.075 0.994 0.98–1.01 0.129
ALT (U/L) 0.999 0.99–1.01 0.806 1.010 0.98–1.03 0.429
AST (U/L) 1.003 0.96–1.04 0.867 0.992 0.96–1.02 0.651
MetS (yes vs. no) 0.800 0.36–1.77 0.127 1.070 0.39–2.93 0.085
MetS (mean) 0.864 0.57–1.30 0.108 0.638 0.39–1.02 0.078
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those who developed renal impairment during
the follow-up period (80.8% vs. 39.6%, P < 0.001
and 25.23% vs. 2%, P < 0.001, respectively). These
patients also had a significantly higher level of cho-
lesterol, LDL-C, triglyceride and liver enzymes
(P < 0.001). However, the level of HDL-Cwasmuch
lower in those who developed renal impairment
during follow-up (P < 0.001).
The incidence of NAFLD was notably higher in
patients with renal impairment during follow-up
than those without (51.9% vs. 29.3%, P < 0.001).
The mean number of MetS risk factors was
3.20 ± 0.96 in patients with renal impairment,
which is higher than those who did not develop
renal impairment during the follow-up period
(2.87 ± 1.07, P = 0.003).Correlative analysis
Correlations of cardiovascular and renal impair-
ment events with NAFLD in addition to other risk
factors were analyzed by forward logistic regres-
sion analysis. NAFLD was the best predictor for
cardiovascular and renal impairment as indicated
by the highest Exp to odds ratio in both (Table 4).Discussion
That NAFLD is significantly associated with an
increased risk of future cardiovascular and renalimpairment events may help to explain underly-
ing mechanisms and may be of clinical impor-
tance for undertaking preventive and therapeutic
strategies. We have prospectively assessed the
prevalence of NAFLD and its association with
the increased incidence of CKD and CVD.
We report that 35.8% of the patients who com-
pleted the follow-up period had sonographic crite-
ria of NAFLD. Of these, 79.4% had type-2 DM,
which supports the results of studies showing
NAFLD prevalence in the 15–30% range in the
general population, its almost certain increase
[13,14], and the higher risk of patients with type-
2 diabetes for developing NAFLD as well as fibro-
sis and cirrhosis. Other studies estimate that
approximately 70–75% of patients with type-2 dia-
betes have NAFLD [11,14].
Our major findings were that NAFLD is associ-
ated with and is the best predictor of increased
risk for cardiovascular and renal impairment
events. These findings are corroborated by a re-
cent study of 10,337 healthy Korean men followed
for approximately 3.5 years, showing that mildly
elevated serum Gamma glutamyl transaminase
(GGT) concentrations, as surrogate markers of
NAFLD [14], are associated with an increased risk
for CKD [15].
Several cross-sectional studies have demon-
strated an association between NAFLD and inti-
ma-media thickness and/or plaques of carotid
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study, Targher et al report that NAFLD is a strong
predictor for future cardiovascular events among
type-2 diabetic patients [17]. As type-2 diabetes
constitutes a very high-risk population for CVD,
it was uncertain whether the study could be
extrapolated to the general population. In a study
of 14,874 middle-aged Finnish patients, mildly ele-
vated GGT levels were independently associated
with an increased risk of ischemic stroke in both
sexes [18]. Among 7,613 middle-aged British men
followed for 11.5 years, elevated GGT levels were
independently associated with a significant in-
crease in mortality from all causes and from
CHD [19].
Studies conducted by Masahide et al. [20] and
Targher et al. [12] reported that both NAFLD
and the MetS were predictors of cardiovascular
events. Since there is a close association between
the MetS – which is a well-known atherogenic
condition – and NAFLD, then the mechanisms
linking NAFLD with cardiovascular events are at
least partly mediated by the atherogenic abnor-
malities of the MetS. In fact, a correlation between
the severity of liver histology of NAFLD and early
carotid atherosclerosis has been reported [16],
while the association between liver histology and
severity of the MetS has been noted as well [21].
In a multivariate analysis based on the model that
included NAFLD and the MetS simultaneously as
covariates, both Targher et al. [12] and Masahide
et al. [20] found that NAFLD but not the MetS re-
tained an independent correlation with cardiovas-
cular events. This suggests that NAFLD is not only
a marker of cardiovascular and renal impairment
events but may also be involved in their
pathogenesis.
The possible mechanisms may include in-
creased oxidative stress, subclinical inflammation,
lipid abnormalities, endothelial dysfunction and
an abnormal adipocytokine profile [22].
Current understanding of the pathogenesis of
NAFLD implies that lipids accumulate in hepato-
cytes, mainly in the form of triacylglycerol, in the
presence of insulin resistance. The biological
mechanisms potentially responsible for acceler-
ated atherogenesis in NAFLDmay either have ori-
gins in the visceral adipose tissue, in the liver, or
in the liver as the target of systemic abnormalities
[23].
A leading role in the development of insulin
resistance, inflammation and NAFLD is likely to
be played by excess adiposity, including ectopic
fat deposition. This ectopic fat is a source of multi-
ple factors involved in atherogenesis, such asNEFA, hormones, pro-inflammatory cytokines
and adipocytokines [24].
Moreover, ectopic fat deposition in visceral adi-
pose depots and heart increases the expression of
several pro-inflammatory mediators leading to lo-
cal macrophage infiltration and associated sys-
temic chronic inflammation [24,25].
The potential implications of our findings for
patient care are that the detection of NAFLD
during ultrasound examination especially in
people with type-2 diabetes should alert clini-
cians to the coexistence or future development
of other complications (including renal impair-
ment and CVD). Thus, identifying people with
NAFLD would highlight a subgroup of indi-
viduals who have type-2 diabetes and who
should be targeted with intensive therapy to
decrease the risk for developing CRD and
CVD events.Limitations
(1) We used an eGFR instead of a directly mea-
sured GFR to define renal impairment. A
recent review reported that current GFR esti-
mates had greater inaccuracy in populations
without known chronic renal impairment
than in those with the disease. However, cur-
rent GFR estimates facilitate the detection,
evaluation, and management of CRD, and
many organizations recommend the use of
equations with eGFR for the evaluation of
renal function [8].
(2) NAFLD diagnosis was based on ultrasound
imaging and exclusion of other secondary
causes of chronic liver disease but was not
confirmed by liver biopsy. It is known that
none of the radiologic features can distin-
guish between non-alcoholic steatohepatitis
and other forms of NAFLD and that only
liver biopsy can assess the severity of dam-
age and the prognosis. However, liver biopsy
would be impossible to perform routinely,
and liver ultrasonography is by far the most
common way of diagnosing NAFLD in clini-
cal practice. It has a sensitivity of 89% and a
specificity of 95% in detecting moderate and
severe steatosis, but this sensitivity is
reduced when hepatic fat infiltration upon
liver biopsy is <33%. Thus, some of those
classified as having no NAFLD in this study
could have underlying NAFLD, despite nor-
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NAFLD is a strong predictor of CVD and renal
impairment. Clinical implications conclude that
ultrasonography of the liver, as a non-invasive
and easily applicable test, may be a useful tool
for risk evaluation of cardiovascular and renal
impairment events. In addition to lifestyle modifi-
cations to reduce fat deposition, patients with
NAFLD may need further exploration for risk fac-
tors of cardiovascular and renal diseases.References
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